Risk Factors for GI Adverse Events in a Phase III Randomized Trial of Bevacizumab in First-Line Therapy of Advanced Ovarian Cancer: A Gynecologic Oncology Group Study

PURPOSE: To evaluate risk factors for GI adverse events (AEs) within a phase III trial of bevacizumab in first-line ovarian cancer therapy. PATIENTS AND METHODS: Women with previously untreated advanced disease after surgery were randomly allocated to six cycles of platinum-taxane chemotherapy plus...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Burger, Robert A., Brady, Mark F., Bookman, Michael A., Monk, Bradley J., Walker, Joan L., Homesley, Howard D., Fowler, Jeffrey, Greer, Benjamin E., Boente, Matthew, Fleming, Gini F., Lim, Peter C., Rubin, Stephen C., Katsumata, Noriyuki, Liang, Sharon X.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2014
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3986384/
https://ncbi.nlm.nih.gov/pubmed/24637999
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2013.53.6524
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados